This trial is active, not recruiting.

Conditions adult giant cell glioblastoma, adult glioblastoma, adult gliosarcoma, recurrent adult brain tumor
Treatments bevacizumab, intensity-modulated radiation therapy, 3-dimensional conformal radiation therapy, proton beam radiation therapy
Phase phase 2
Target VEGF
Sponsor Radiation Therapy Oncology Group
Collaborator National Cancer Institute (NCI)
Start date December 2012
End date March 2018
Trial size 182 participants
Trial identifier NCT01730950, NCI-2012-01732, NCT02671981, RTOG-1205, U10CA021661


This randomized phase II trial studies how well bevacizumab with or without radiation therapy works in treating patients with recurrent glioblastoma. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. It is not yet know whether bevacizumab is more effective with or without radiation therapy in treating patients with recurrent glioblastoma

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
(Active Comparator)
Patients receive bevacizumab IV over 30-90 minutes every 2 weeks.
bevacizumab anti-VEGF humanized monoclonal antibody
Given IV
Patients receive bevacizumab as patients in arm I and undergo radiation therapy using IMRT, 3D-CRT, or proton beam RT 5 days a week for 2 weeks.
bevacizumab anti-VEGF humanized monoclonal antibody
Given IV
intensity-modulated radiation therapy IMRT
Undergo IMRT
3-dimensional conformal radiation therapy 3D conformal radiation therapy
Undergo 3D-CRT
proton beam radiation therapy
Undergo proton beam RT

Primary Outcomes

Overall survival
time frame: From randomization to the date of death or the last follow-up. Analysis occurs after XX deaths have bee reported.

Secondary Outcomes

Objective response
time frame: Analysis occurs at the same time as the primary outcome analysis.
6-month Progression-free survival (PFS) rate
time frame: Up to 6-months
time frame: Analysis occurs at the same time as the primary outcome analysis.
Grade 3+ acute or delayed CNS toxicity rate
time frame: Analysis occurs at the same time as the primary outcome analysis.

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Histopathologically proven diagnosis of glioblastoma or variants (gliosarcoma, giant cell glioblastoma etc); patients will be eligible if the original histology was lower-grade glioma and a subsequent diagnosis of glioblastoma or gliosarcoma is made - Patients who did not have recent surgery for their glioblastoma must have shown unequivocal radiographic evidence for tumor progression by contrast-enhanced magnetic resonance imaging (MRI) scan (or computed tomography [CT] scan for patients with non-compatible devices) CT scan within 21 days prior to registration. * Note: Patients who did have surgery with a post-operative contrast-enhance scan falling outside the 5 week window prior to registration, must have a repeat MRI scan (or CT scan for patients with non-compatible devices) within 21 days prior to registration. - Patients also must have passed an interval of 6 months or greater between completion of prior radiotherapy and registration; if patients have not passed an interval of at least 6 months, they may still be eligible if they meet one or more of the following criteria: - New areas of tumor outside the original radiotherapy fields as determined by the investigator, or - Histologic confirmation of tumor through biopsy or resection, or - Nuclear medicine imaging, magnetic resonance (MR) spectroscopy, or MR perfusion imaging consistent with true progressive disease, rather than radiation necrosis obtained within 28 days of registration AND an interval of at least 90 days between completion of radiotherapy and registration - Patients unable to undergo MR imaging because of non-compatible devices can be enrolled provided CT scans are obtained and are of sufficient quality; patients without non-compatible devices may not use CT scans performed to meet this requirement - Prior history of standard dose CNS radiation of 60 Gy in 30 fractions or 59.4 Gy in 1.8 Gy fractions, or equivalent or lower doses - Patients who have received prior treatment with non-standard radiation therapy (RT) dose and fractionation, interstitial brachytherapy, stereotactic radiosurgery, etc. are eligible - Patients must have recovered from the toxic effects of prior therapy, and there must be a minimum time of 28 days prior to registration from the administration of any investigational agent or prior cytotoxic therapy with the following exceptions: - 14 days from administration of vincristine - 42 days from administration of nitrosoureas - 21 days from administration of procarbazine - Patients having undergone recent resection of their glioblastoma (within 5 weeks prior to registration) must have recovered from the effects of surgery; for CNS related core or needle biopsies, a minimum of 7 days must have elapsed prior to registration - Residual disease following resection of recurrent glioblastoma is not mandated for eligibility into the study; to best assess the extent of residual disease post-operatively, a post-operative or intra-operative MRI scan (or CT scan for patients with non-compatible devices) must be performed prior to registration and should be within 96 hours post surgery (although 24 hours would be optimum) - History/physical examination, including neurologic examination, within 14 days prior to registration - Karnofsky performance status >= 60 within 14 days prior to registration - Complete blood count (CBC)/differential obtained within 14 days prior to registration, with adequate bone marrow function - Absolute neutrophil count (ANC) >= 1,500 cells/mm^3 - Platelets >= 75,000 cells/mm^3 - Hemoglobin >= 9.0 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin (Hgb) >= 9.0 g/dl is acceptable) - Total bilirubin =< 2.0 mg/dL - Serum glutamic oxaloacetic transaminase (SGOT) or aspartate aminotransferase (AST) =< 2.5 times the upper limit of normal - Serum creatinine =< 1.8 mg/dL - Urine protein creatinine (UPC) ratio >= 1.0 within 14 days prior to registration OR urine dipstick for proteinuria >= 2+ (patients discovered to have >= 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate =< 1g of protein in 24 hours to be eligible) - Note: UPC ratio of spot urine is an estimation of the 24-hour urine protein excretion; a UPC ratio of 1 is roughly equivalent to a 24-hour urine protein of 1 gm; UPC ratio is calculated using one of the following formulas: - [urine protein]/[urine creatinine]: if both protein and creatinine are reported in mg/dL - [(urine protein) x 0.088]/[urine creatinine]: if urine creatinine is reported in mmol/L - Patients must not be pregnant (positive pregnancy test) or breast feeding; pregnancy test must be done within 14 days prior to registration; effective contraception (men and women) must be used in patients of child-bearing potential while on trial and for 6 months after - Patients on full-dose anticoagulants (e.g., warfarin or low molecular weigh [LMW] heparin) must meet both of the following criteria: - No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices) - In-range international normalized ratio (INR) (usually between 2 and 3) on a stable dose of oral anticoagulant or on a stable dose of low molecular weight heparin, within 14 days prior to registration - Patient must be able to provide study-specific informed consent prior to study entry Exclusion Criteria: - More than three relapses - Infratentorial or leptomeningeal evidence of recurrent disease - Recurrent or persistent tumor greater than 6 cm in maximum diameter - Prior therapy with an inhibitor of vascular endothelial growth factor (VEGF) or VEGFR (including bevacizumab) - Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 1 year (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible) - Severe, active co-morbidity, defined as follows: - Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months prior to registration - Transmural myocardial infarction within the last 6 months prior to registration - History of stroke or transient ischemic attack within 6 months prior to registration - Significant vascular disease (e.g., aortic aneurysm, history of aortic dissection) or clinically significant peripheral vascular disease - Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration - Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration - Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for liver function other than screening panel and coagulation parameters are not required for entry into this protocol - Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; the need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive; protocol specific requirements may also exclude immuno-compromised patients - Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic - Prior allergic reaction to the study drug (bevacizumab) - Prior history of hypertensive crisis or hypertensive encephalopathy - History of a non-healing wound, ulcer, or bone fracture within 90 days (3 months) prior to registration - Gastrointestinal bleeding or any other hemorrhage/bleeding event Common Terminology Criteria for adverse Events (CTCAE), v. 4 grade 3 or greater within 30 days prior to registration - Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to registration (with the exception of craniotomy)

Additional Information

Principal investigator Christina Tsien
Description PRIMARY OBJECTIVES: I. To establish an improvement in overall survival in recurrent glioblastoma (GBM) patients receiving bevacizumab and re-irradiation compared with patients receiving bevacizumab alone. SECONDARY OBJECTIVES: I. To estimate and compare the rate of objective response in patients with measurable disease. II. To estimate and compare the 6-month progression-free survival rate. III. To estimate and compare progression-free survival. IV. To estimate and compare the rate of treatment adverse events. V. To estimate and compare the rate of grade 3+ acute or delayed central nervous system (CNS) toxicity. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive bevacizumab intravenously (IV) over 30-90 minutes every 2 weeks. ARM II: Patients receive bevacizumab as patients in arm I and undergo radiation therapy using intensity-modulated radiation therapy (IMRT), 3-dimensional conformal radiation therapy (3D-CRT), or proton beam radiation therapy (RT) 5 days a week for 2 weeks. In both arms, courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 2 months for 1 year, every 6 months for 1 year and then annually thereafter.
Trial information was received from ClinicalTrials.gov and was last updated in October 2016.
Information provided to ClinicalTrials.gov by Radiation Therapy Oncology Group.